Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies
Publish Date: 2026-05-26 11:13:00
Source Domain: www.biospace.com
- Biomunex Pharmaceuticals has announced two strategic collaborations with AI-driven companies, Gordion Bioscience and Tangramed Biotech, to integrate AI into its R&D and support next generation immunotherapies in oncology.
- The collaboration with Gordion Bioscience aims to identify novel bispecific target combinations using patient-derived biological network analysis and computational target discovery.
- The partnership with Tangramed Biotech focuses on uncovering and prioritizing actionable therapeutic opportunities using multimodal target-combination discovery and generative AI.
- Both collaborations are set to leverage Biomunex’s proprietary BiXAb® platform to accelerate the discovery and development of novel immunotherapies in oncology.
- Biomunex aims to combine its BiXAb® technology with these AI-driven approaches to optimize target selection, shorten discovery timelines, and increase the probability of translational success.
